Informação da revista
Vol. 42. Núm. 7.
Páginas 681-682 (julho 2023)
Partilhar
Partilhar
Baixar PDF
Mais opções do artigo
Vol. 42. Núm. 7.
Páginas 681-682 (julho 2023)
Letter to the Editor
Acesso de texto completo
Takotsubo syndrome and lactation: Further insights
Síndrome de Takotsubo e lactação: mais informações
Visitas
1168
Diogo Rodrigues-Brása,b
a Cardiology Department, Hospital Espírito Santo Évora EPE, Évora, Portugal
b Cardiovascular Responsibility Centre (CRIA), Hospital Espírito Santo Évora EPE, Évora, Portugal
Este item recebeu
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Texto Completo

Our team is glad that this case report has raised interest in the role of estrogen in Takotsubo syndrome (TTS).1

Even after many years of research, the pathophysiology of Takotsubo syndrome cannot be explained by a unified hypothesis.2,3 This probably means that TTS is a complex entity in which multifactorial causes are constantly weighted (from its biological background to environment/triggers and underlying disease), leading to the probability of suffering or not from this phenotype.

Sex disparity, especially being female, is a well-recognised predisposing factor for clinical probability of TTS4 and it is the main contributing factor to the InterTAK Diagnostic score.5 However, this relationship is not well established in pre-menopausal women. The underlying mechanism is related to the cardioprotective action of estrogen, a hormone that may be inhibited in some life stages of a premenopausal female – such as during peripartum period and lactation. Solid evidence to ascertain this hypothesis in humans is still lacking, and the available data remain animal-based.6–8 Nonetheless, we believe that these stages of a female's reproductive life may represent an important element in the “cocktail” of multifactorial causes leading to TTS. After the journal's acceptance of our report, in 2019, another case of a lactating young woman that suffered from TTS (in this case, reverse TTS) was published. In this case, the patient developed cardiogenic shock during hospital stay, and was discharged with normal left ventricle ejection fraction.9

We gladly report that our patient,1 a 22-year-old lactating woman, whose TTS event reports back to 2017, has been followed-up ever since and is free from cardiovascular symptoms, with normal echocardiogram and no recurrences. Neither strain/strain rate nor diastolic stress testing has been performed. Even though she is free from cardiovascular disease, we have recommended a cardiology appointment and coordination with gynaecology/obstetrics in the event of new pregnancies. She has not had any more children since then.

The authors thank Yalta et al. for the appropriate comment regarding our report. Both discussed hypotheses for the physiopathology of this case, besides the protection role of estrogens, are relevant and they have one common link – the role of prolactin in inhibiting the gonadal axis and enabling a peripartum cardiomyopathy-like syndrome due to 16 kDa prolactin fragment. Since there is no available biochemical/molecular evidence in this case, we can only hypothesize that this is a plausible explanation.

Since there is no solid evidence to sustain the recommendation to abstain from further breastfeeding or upfront anti-prolactin agents (patient has normal left ventricle ejection fraction and no confirmed peripartum cardiomyopathy10), we would refrain from giving this kind of advice to the patient.

The patient was discharged asymptomatic and with normal left ventricle ejection fraction. We are not sure of the requirement for further workup regarding potential subclinical myocardial dysfunction based on the available information – nevertheless it could be interesting to interpret diastolic stress testing and myocardial strain in a clinical research setting.

Fortunately, TTS in young women is a rare diagnosis, which leads to a lack of high-grade evidence. This is a setting in which case reports and case report series are of high value. We hope that our publication keeps raising awareness of TTS during lactation, and if possible, we are able to conduct further research.

Funding

None declared.

Conflict of interest

None declared.

References
[1]
D. Rodrigues Brás, P. Semedo, B. Cordeiro Piçarra, et al.
Takotsubo syndrome in a breast-feeding young woman: highlighting the protection of oestrogens?.
Rev Port Cardiol, 41 (2022),
[2]
A.R. Lyon, R. Citro, B. Schneider, et al.
Pathophysiology of Takotsubo syndrome: JACC state-of-the-art review.
J Am Coll Cardiol, 77 (2021), pp. 902-921
[3]
Y. Sethi, H. Murli, O. Kaiwan, et al.
Broken heart syndrome: evolving molecular mechanisms and principles of management.
J Clin Med, 12 (2022), pp. 125
[4]
J. Ghadri, I.S. Wittstein, A. Prasad, et al.
International expert consensus document on Takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology.
Eur Heart J, 39 (2018), pp. 2032-2046
[5]
J.R. Ghadri, V.L. Cammann, S. Jurisic, et al.
A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry.
Eur J Heart Fail, 19 (2017), pp. 1036-1042
[6]
R. Brenner, D. Weilenmann, M.T. Maeder, et al.
Clinical characteristics, sex hormones, and long-term follow-up in Swiss postmenopausal women presenting with takotsubo cardiomyopathy.
Clin Cardiol, 35 (2012), pp. 340-347
[7]
A. Waqar, A. Jain, C. Joseph, et al.
Cardioprotective role of estrogen in takotsubo cardiomyopathy.
Cureus, 14 (2022), pp. 3
[8]
A.R. Almeida.
What is the role of estrogen in predisposition to Takotsubo syndrome throughout a woman's reproductive life?.
Rev Port Cardiol [Internet], 41 (2022), pp. 889-890
[9]
C.M. Pires, S. Rocha, N. Salomé, et al.
A life-threatening reverse Takotsubo syndrome in a young breastfeeding woman: a case report.
Eur Heart J – Case Rep, 5 (2021), pp. 1-8
[10]
V. Regitz-Zagrosek, J.W. Roos-Hesselink, J. Bauersachs, et al.
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.
Eur Heart J, 39 (2018), pp. 3165-3241
Baixar PDF
Idiomas
Revista Portuguesa de Cardiologia
Opções de artigo
Ferramentas
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.